DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
GS-9674 is an investigational drug.
There have been 10 clinical trials for GS-9674. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].
There are seven US patents protecting this investigational drug and ninety-four international patents.
Recent Clinical Trials for GS-9674
|Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)||Novo Nordisk A/S||Phase 2|
|Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)||Gilead Sciences||Phase 2|
|Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis||Gilead Sciences||Phase 1|
Top disease conditions for GS-9674
Top clinical trial sponsors for GS-9674
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GS-9674||Start Trial||FXR agonists and methods for making and using||Salk Institute for Biological Studies (La Jolla, CA)||Start Trial|
|GS-9674||Start Trial||FXR (NR1H4) binding and activity modulating compounds||GILEAD SCIENCES, INC. (Foster City, CA)||Start Trial|
|GS-9674||Start Trial||FXR (NR1H4) modulating compounds||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|GS-9674||Start Trial||FXR (NR1H4) binding and activity modulating compounds||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GS-9674||European Patent Office||3116878||2034-03-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|